product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
Vaccinia Virus A33R Antibody [Biotin] - (Copenhagen)
catalog :
NBP3-43778B
quantity :
0.1 ml
price :
449 USD
clonality :
polyclonal
host :
domestic rabbit
conjugate :
biotin
application :
ELISA
more info or order :
product information
brand :
Novus
master code :
NBP3-43778B
SKU :
NBP3-43778B
product name :
Vaccinia Virus A33R Antibody [Biotin] - (Copenhagen)
sizes available :
0.1 ml
description :
The Vaccinia Virus A33R Antibody [Biotin] - (Copenhagen) from NBP3-43778B is a 6.7e-05 antibody to . This antibody reacts with virus.
target :
Vaccinia Virus A33R
category :
Primary Antibodies
buffer :
PBS
clonality :
Polyclonal
conjugate :
Biotin
all_available conjugate :
Biotin
dilution :
ELISA
host :
Rabbit
immunogen :
Produced in rabbits immunized with purified, recombinant Vaccinia Virus A33R (Copenhagen) (Uniprot#: P68616; Val57-Asn185).
isotype :
IgG
purity :
Antigen and protein A Affinity-purified
species :
Virus
applications :
ELISA
USD :
449 USD
alt names :
OPG161
storage :
Store at 4C in the dark.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
browse more products
- Vaccinia Virus A33R Antibody [Allophycocyanin] - (Copenhagen) | NBP3-43778APC
- Vaccinia Virus A33R Antibody [Alexa Fluor Plus 680] - (Copenhagen) | NBP3-43778AFP680
- Vaccinia Virus A33R Antibody [Alexa Fluor Plus 647] - (Copenhagen) | NBP3-43778AFP647
- Azurocidin/CAP37/HBP Antibody [DyLight 680] | NBP2-99431FR
- Vaccinia Virus A33R Antibody [Alexa Fluor Plus 594] - (Copenhagen) | NBP3-43778AFP594
questions and comments
